Patents
Literature
4 results about "Histone deacetylase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Histone deacetylases (EC 3.5.1.98, HDAC) are a class of enzymes that remove acetyl groups (O=C-CH₃) from an ε-N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. Its action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non-histone proteins.
Combination treatments using epigenetic inhibition and syngri-mediated frataxin expression
PCT designated stageWO2026107052A1Organic active ingredientsNervous disorderDiseaseHistone deacetylase
The present disclosure relates to pharmaceutical compositions comprising a synthetic transcription elongation factor (SynTEF) and an epigenetic inhibitor (e.g., a histone deacetylase (HDAC) inhibitor). As detailed herein, the disclosed compositions and combinations can be used to target FGF14b in Friedreich's ataxia (FRDA / FA), SCA27b, and other GAA-repeat based diseases.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Use of MEF2 binding molecules to inhibit HDAC-MEF2 interaction
PCT designated stageWO2026107183A1Nervous disorderPeptide/protein ingredientsMef2Histone deacetylase
An isolated myocyte enhancer factor-2 (MEF2) binding molecule comprising an amino acid sequence of: X1 X2 X3 X4 A X6 A S X9 X10 V K X13 X14 L X16 E X18 X19 L X21 K X23 X24 X25 X26, in which X1 is S or G, or is removed; X2 is K or R; X3 is R or E; X4 is S or R; X6 is V or I; X9 is S or T; X10 is V or E; X13 is Q, M, or L; X14 is K or R; X16 is A or Q; X18 is V or F; X19 is I, V, or L; X21 is K, N, or S; X23 is Q, K, or S; X24 is Q or A, or is removed; X25 is A or T, or is removed; and X26 is A or K. In addition, use of the isolated MEF2 binding molecule to inhibit binding of histone deacetylase (HD AC) and MEF2 in a cell, and to inhibit HDAC- induced suppression of MEF2-dependent gene expression in a cell.
Owner:GEORGETOWN UNIV
Class iia histone deacetylase (HDAC) degrader ligands and methods of use thereof
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant activity of at least one class IIa histone deacetylase (HDAC4 / 5 / 7 / 9).
Owner:DANA FARBER CANCER INSTITUTE INC
Methods of pancreatic beta cell differentiation
PendingCN122349556APluripotential stem cellHistone deacetylase
The present disclosure provides a method of differentiating human pluripotent stem cells (hPSCs) into mature pancreatic beta cells, the method comprising contacting human pluripotent stem cell-derived differentiated immature pancreatic beta cells with a histone deacetylase (HDAC) inhibitor.
Owner:HANGZHOU RUIPU CHENCHUANG TECH CO LTD